Aileron Therapeutics Appoints New Chief Medical Officer
Ticker: RNTX · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics Inc (RNTX) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, cmo
Related Tickers: KAD
TL;DR
Aileron Therapeutics just hired a new CMO, Dr. Christopher P. Miller, to lead their clinical strategy.
AI Summary
Aileron Therapeutics, Inc. announced on February 29, 2024, that its Board of Directors has appointed Dr. Christopher P. Miller as Chief Medical Officer. Dr. Miller, who previously served as Chief Medical Officer at Kadmon Pharmaceuticals, will lead Aileron's clinical development strategy. The company also reported on the election of new directors and changes to its compensatory arrangements.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's drug development pipeline and future clinical trial strategies.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategy or challenges that may affect the company's future performance.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- Christopher P. Miller (person) — Appointed Chief Medical Officer
- Kadmon Pharmaceuticals (company) — Previous employer of new CMO
- February 29, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer of Aileron Therapeutics?
Dr. Christopher P. Miller has been appointed as the new Chief Medical Officer of Aileron Therapeutics.
When was this appointment announced?
The appointment was announced on February 29, 2024.
What was Dr. Miller's previous role?
Dr. Miller previously served as Chief Medical Officer at Kadmon Pharmaceuticals.
What is the primary responsibility of the new Chief Medical Officer?
The new Chief Medical Officer will lead Aileron's clinical development strategy.
What other items were reported in this 8-K filing?
The filing also reported on the election of directors and changes to compensatory arrangements of certain officers.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-03-01 16:07:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d797289d8k.htm (8-K) — 23KB
- 0001193125-24-055936.txt ( ) — 139KB
- alrn-20240229.xsd (EX-101.SCH) — 3KB
- alrn-20240229_lab.xml (EX-101.LAB) — 17KB
- alrn-20240229_pre.xml (EX-101.PRE) — 11KB
- d797289d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: March 1, 2024 By: /s/ Manuel C. Alves-Aivado Manuel C. Alves-Aivado, M.D., Ph.D. Chief Executive Officer